Jawansa (Cuscuta reflexa)

Jawansa (Cuscuta reflexa) is a parasitic plant containing flavonoids and alkaloids traditionally used in Unani medicine for inflammation management. Its potential antimicrobial and anti-inflammatory effects are suggested by preclinical studies but lack clinical validation.

Origin & History

Jawansa (Cuscuta reflexa) is a golden yellow, leafless parasitic herb that lacks chlorophyll and roots, twining around host plants throughout India, Nepal, Bangladesh, Pakistan, and Myanmar. The whole plant is harvested and typically extracted using solvents for phytochemical analysis, revealing compounds including flavonoids, coumarins, triterpenoids, and fatty acids.

Historical & Cultural Context

In Myanmar, Jawansa is known as shwe-new or shwe-nwe-pin and has been traditionally used to treat inflammation and blood irregularities. The herb has historical use across traditional medicine systems in India, Nepal, Bangladesh, and Pakistan, though the exact duration of use is unspecified.

Health Benefits

• No clinically proven health benefits - all research limited to preclinical studies
• Traditional use for inflammation management - based on historical use in Myanmar, not clinical evidence
• Potential antimicrobial properties - suggested by in vitro studies only
• Traditional blood regulation support - based on historical use, no clinical validation
• Possible antitumor activity - attributed to isolated compounds in laboratory studies only

How It Works

Jawansa's flavonoids, particularly quercetin and kaempferol derivatives, may modulate inflammatory pathways by inhibiting nuclear factor-kappa B (NF-κB) activation. The alkaloids present in Cuscuta reflexa potentially exert antimicrobial effects through membrane disruption and enzyme inhibition in pathogenic microorganisms.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Cuscuta reflexa. All available research is limited to phytochemical characterization and in vitro/in vivo preclinical studies, with no PubMed PMIDs for human trials identified.

Clinical Summary

No human clinical trials have been conducted on Jawansa supplementation. Available research consists entirely of in vitro and animal studies examining extract concentrations ranging from 100-500 mg/kg body weight. Preclinical studies suggest anti-inflammatory activity in rodent models, but translation to human efficacy remains unestablished. Current evidence is insufficient to support any health claims.

Nutritional Profile

{"macronutrients": {"protein": "0.5-1.0 g per 100 g", "fiber": "1.0-2.0 g per 100 g"}, "micronutrients": {"vitamin_c": "5-10 mg per 100 g", "calcium": "20-30 mg per 100 g", "iron": "0.5-1.0 mg per 100 g"}, "bioactive_compounds": {"flavonoids": "0.1-0.5 mg per 100 g", "alkaloids": "0.1-0.3 mg per 100 g"}, "bioavailability_notes": "Nutrient absorption may vary due to the presence of antinutritional factors; limited data on bioavailability."}

Preparation & Dosage

No clinically studied dosage ranges or standardized forms have been established for Cuscuta reflexa due to the absence of human clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Limited to traditional combinations only - no evidence-based synergistic ingredients identified

Safety & Interactions

Safety data for Jawansa in humans is extremely limited due to lack of clinical studies. Traditional use suggests generally recognized as safe status in small amounts, but optimal dosing and long-term effects are unknown. Potential interactions with anticoagulant medications exist due to traditional blood regulation claims. Pregnant and breastfeeding women should avoid use due to insufficient safety data.